For research use only. Not for therapeutic Use.
Phortress is a high affinity AhR ligand that elicits antitumor activity by inducing transcription of CYP1A1[1][2].
| Catalog Number | I008749 |
| CAS Number | 328087-38-3 |
| Synonyms | (2S)-2,6-diamino-N-[4-(5-fluoro-1,3-benzothiazol-2-yl)-2-methylphenyl]hexanamide;dihydrochloride |
| Molecular Formula | C20H25Cl2FN4OS |
| Purity | ≥95% |
| InChI | InChI=1S/C20H23FN4OS.2ClH/c1-12-10-13(20-25-17-11-14(21)6-8-18(17)27-20)5-7-16(12)24-19(26)15(23)4-2-3-9-22;;/h5-8,10-11,15H,2-4,9,22-23H2,1H3,(H,24,26);2*1H/t15-;;/m0../s1 |
| InChIKey | QZSMNTOCJVVFEU-CKUXDGONSA-N |
| SMILES | CC1=C(C=CC(=C1)C2=NC3=C(S2)C=CC(=C3)F)NC(=O)C(CCCCN)N.Cl.Cl |
| Reference | [1]. Bradshaw TD, et al. In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles. Br J Cancer. 2002 Apr 22;86(8):1348-54. [2]. Bradshaw TD, Westwell AD. The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate. Curr Med Chem. 2004 Apr;11(8):1009-21. |
